Is Breakout in Clinuvel Pharmaceuticals (ASX: CUV) Signalling a Sustainable Bullish Reversal?
CLINUVEL is a global photomedicine group commercialising SCENESSE for rare disorders while advancing vitiligo, ACTH and porphyria programs. Recent share strength reflects EMA vitiligo progress, stronger pipeline visibility and Nasdaq listing plans, though Phase III, regulatory and competition risks remain.
Avecho Biotechnology (ASX: AVE): Breakout Above Long-Term Resistance Puts Trend Sustainability in Focus
Avecho’s rally reflects Phase III CBD-insomnia progress, patent wins, and improving investor confidence. The biotech commercialises its TPM delivery platform across pharma, skincare, and animal health, while its production business supports higher-risk human health programs.
Mesoblast (ASX: MSB) Shares Declined Despite Ryoncil Momentum as Investors Lock In Profits
Mesoblast (ASX: MSB) is transitioning into a commercial-stage biotech as Ryoncil® sales accelerate and its late-stage pipeline advances. While the share price has eased after a strong rally, growing revenue, improving cash flow, and multiple clinical catalysts continue to support its long-term outlook.
Inoviq (ASX: IIQ)'s Breakout Reverses Hard: IIQ Slides After EXO-OC Study Reset
Inoviq shares plunged after sample-quality issues delayed validation of its EXO-OC ovarian cancer test, despite improved algorithm performance. The sharp reversal has shifted investor focus from growth potential to execution risks, timelines, and confidence in the company’s development strategy.
Telstra Group (ASX: TLS) - A Defensive Cash Compounder with Embedded Digital Optionality
We view Telstra as a highly resilient, structurally advantaged cash-generating business within the Australian equity market, offering strong earnings quality and downside protection despite limited headline growth. Its focus on network leadership, disciplined capital management and monetisation of digital and infrastructure assets supports stable free cash flow and reliable capital returns, particularly in a softer macro environment. We believe the market continues to undervalue Telstra’s leverage to long-term data demand, the durability of its mobile economics, and the embedded optionality in InfraCo and enterprise digital services.
Why is SportsHero's (ASX: SHO) share price rising and how much higher can it go?
SportsHero (ASX: SHO) is an early-stage Australian sports gamification and media company focused on mobile-first prediction and gaming platforms across Southeast Asia, primarily Indonesia. It offers leveraged exposure to regional digital gaming growth but carries high execution, funding and profitability risk typical of small-cap platform build-outs.